Breast Cancer in Morocco: A Literature Review

Slaoui, Meriem; Rachid, R.; Ibrahimi, Azeddine; Attaleb, Mohammed; Mzibri, Mohammed El; Amrani, M.

doi:10.7314/apjcp.2014.15.3.1067

Cited by 30 publications

(17 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the availability of substantial information regarding cancer risks in BRCA1/2 PSV carriers, the amount of information available to suggest that this PSV arose no more than 1500 years ago, suggesting that it was transmitted from the middle east to Africa, and did not arise there before the original migration of individuals out of Africa (Laitman et al, 2013). However, this PSV has been reported in native Africans (Zoure et al, 2018) and has arisen in multiple populations independently, so it is not known whether this PSV is a new PSV at a locus that demonstrates high mutation rates, or if it is the common Jewish founder PSV, which has been observed in Middle Eastern or North African populations (Laitman et al, 2013;Slaoui et al, 2014;Zoure et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry

et al. 2019

View full text Add to dashboard Cite

BRCA1 and BRCA2 (BRCA1/2) pathogenic sequence variants (PSVs) confer elevated risks of multiple cancers. However, most BRCA1/2 PSVs reports focus on European ancestry individuals. Knowledge of the PSV distribution in African descent individuals is poorly understood. We undertook a systematic review of the published literature and publicly available databases reporting BRCA1/2 PSVs also accessed the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) database to identify African or African descent individuals. Using these data, we inferred which of the BRCA PSVs were likely to be of African continental origin. Of the 43,817 BRCA1/2 PSV carriers in the CIMBA database, 469 (1%) were of African descent. Additional African descent individuals were identified in public databases (n = 291) and the literature (n = 601). We identified 164 unique BRCA1 and 173 unique BRCA2 PSVs in individuals of African ancestry. Of these, 83 BRCA1 and 91 BRCA2 PSVs are of likely or possible African origin. We observed numerous differences in the distribution of PSV type and function in African origin versus non‐African origin PSVs. Research in populations of African ancestry with BRCA1/2 PSVs is needed to provide the information needed for clinical management and decision‐making in African descent individuals worldwide.

show abstract

Section: Discussionmentioning

confidence: 99%

BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Highest rates were seen in North America and Western Europe, and lower rates observed in Japan (Aliasghar, 2014;Ramesh, 2014). Prevalence of this cancer is lower in Asian countries compare to developed countries, but it is increasing (Aliasghar et al, 2014;Slaoui et al, 2014). In Iran, the highest rate of breast cancer was observed in Tehran (55.8/10 5 ) and Khuzestan (41/10 5 ) provinces (Kaviani, 2011).…”

Section: Discussionmentioning

confidence: 99%

Incidence of Cancers in Kuzestan Province of Iran: Trend from 2004 to 2008

Amoori¹,

Mirzaei²,

Cheraghi³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Interestingly, the average age of onset in this region is more than 10 years below that of Western countries . In Morocco, average onset occurs at 48 years, with 7% of cases diagnosed at less than 35 years . In addition, the size and grade of breast tumors at diagnosis are higher in North Africa than elsewhere .…”

mentioning

confidence: 92%

“…Therefore, the identification and geographic mapping of founder mutations can lead to cheaper and quicker mutational screening of high‐risk patients. However, to date, only one founder BRCA1 mutation (c.798_799delTT) specific to North African populations has been described .…”

mentioning

confidence: 99%

Identification of a founder BRCA1 mutation in the Moroccan population

et al. 2016

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequent cancer among women in Morocco. However, the role of the most prevalent BC-predisposing genes, BRCA1 and BRCA2, has been largely unexplored. To help define the role of BRCA1 in BC in Morocco, we characterized the first potential BRCA1 founder mutation in this population. Genetic testing of BRCA1 and BRCA2 in BC high-risk families identified mutation BRCA1 c.5309G>T, p.(Gly1770Val) or G1770V in five independent families from Morocco, suggesting a founder effect. To confirm this hypothesis, haplotype construction was performed using seven intragenic and flanking BRCA1 microsatellite markers. Clinical data were also compiled. Clinical data from carriers of mutation G1770V correspond to data from carriers of BRCA1 pathogenic mutations. Microsatellite analysis showed a common haplotype for the five families in a region comprising 1.54 Mb, confirming G1770V as the first specific founder BRCA1 mutation in the Moroccan population. Our findings contribute to a better understanding of BC genetics in the Moroccan population. Nevertheless, comprehensive studies of mutation G1770V in large series of BC patients from Morocco are needed to assess the real prevalence of this mutation and to improve genetic testing and risk assessment in this population.

show abstract

Breast Cancer in Morocco: A Literature Review

Cited by 30 publications

References 57 publications

BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry

BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry

Incidence of Cancers in Kuzestan Province of Iran: Trend from 2004 to 2008

Identification of a founder BRCA1 mutation in the Moroccan population

Contact Info

Product

Resources

About